Our Research

Houston Methodist COVID-19 Research Thumbnail
Coronavirus Disease 2019 (COVID-19) Research

Houston Methodist researchers are studying the novel coronavirus disease 2019. Read more...

At Houston Methodist, fostering innovations with the potential for clinical application is at the very heart of what we do. Our interdisciplinary teams of clinicians and researchers are committed to streamlining the process of translating discoveries into treatments and cures for our patients.


Learn more about how we are delivering on our commitment to leading medicine from the earliest phase of discovery in a lab to the testing new drugs or therapies in clinical trials.


Our Annual Report

Novel medical technology for craniomaxillofacial surgery is cleared by FDA for market

Doctor using AnatomicAligner, a new FDA-approved Methodist-built software program, on an iPad.

Houston Methodist recently reached a major milestone, receiving U.S. Food and Drug Administration (FDA) 510(k) clearance to market the AnatomicAligner, a novel, comprehensive software program used to improve planning for craniomaxillofacial (CMF) surgeries. Learn more>

Houston Methodist is first to treat COVID-19 with convalescent plasma therapy

Computer-generated image of a Coronavirus

Houston Methodist was the first in the nation to receive FDA approval to use convalescent plasma for COVID-19 patients and the first to publish a peer-reviewed study on the therapy, revealing 19 of 25 critically ill patients showed improvement. Learn more>


New discovery may lead to drugs supporting long-term survival

Liver Feature Image

Xian Chang Li, MD, PhD, Max and Lillie Frosch Centennial Chair in Transplant Research, is co-author of a study in June’s Science, suggesting the immune system can remember foreign cells, paving the way for drugs that lengthen survival of transplanted organs. Learn more>

Cardiologist awarded SCCT Cardiovascular Disease Prevention Award

Khurram Nasir, MD, MPH, Department of Cardiology, co-director, Center for Outcomes Research, DeBakey Heart & Vascular Center, was awarded the Society of Cardiovascular Computed Tomography (SCCT) Arthur S. Agatston Cardiovascular Disease Prevention Award. Learn more>


Latest News

Monday, October 19, 2020 Clinical trials at Houston Methodist Cancer Center at Sugar Land offer hope for local cancer patients
The Houston Methodist Cancer Center at Sugar Land is extending the range of care available to local patients through a growing number of clinical trials typically unavailable in a community setting.   Clinical trials are controlled, evidence-based research to determine if new therapies are effective...
Read more
Thursday, October 8, 2020 Experimental glioblastoma therapy shows curative powers in mice models
Houston Methodist researchers found that mice harboring human glioblastoma tumors in their brains had greatly enhanced survival and weight gain when given a newly developed prodrug. This mitochondrial-targeted prodrug - an inactive compound that cancer cells selectively metabolize to produce an acti...
Read more
Tuesday, October 6, 2020 60-day follow-up of 300+ COVID-19 patients demonstrates convalescent plasma therapy is safe and effective
A detailed, extensive two-month follow-up study of 351 COVID-19 patients treated with convalescent plasma therapy at Houston Methodist concludes that those patients receiving convalescent plasma with a very high antibody content – or high titer – within 72 hours of hospitalization were significantly...
Read more